Cargando…
Bladder Cancer and Urothelial Impairment: The Role of TRPV1 as Potential Drug Target
Urothelium, in addition to its primary function of barrier, is now understood to act as a complex system of cell communication that exhibits specialized sensory properties in the regulation of physiological or pathological stimuli. Furthermore, it has been hypothesized that bladder inflammation and...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4034493/ https://www.ncbi.nlm.nih.gov/pubmed/24901005 http://dx.doi.org/10.1155/2014/987149 |
_version_ | 1782317971198181376 |
---|---|
author | Mistretta, Francesco Buffi, Nicolò Maria Lughezzani, Giovanni Lista, Giuliana Larcher, Alessandro Fossati, Nicola Abrate, Alberto Dell'Oglio, Paolo Montorsi, Francesco Guazzoni, Giorgio Lazzeri, Massimo |
author_facet | Mistretta, Francesco Buffi, Nicolò Maria Lughezzani, Giovanni Lista, Giuliana Larcher, Alessandro Fossati, Nicola Abrate, Alberto Dell'Oglio, Paolo Montorsi, Francesco Guazzoni, Giorgio Lazzeri, Massimo |
author_sort | Mistretta, Francesco |
collection | PubMed |
description | Urothelium, in addition to its primary function of barrier, is now understood to act as a complex system of cell communication that exhibits specialized sensory properties in the regulation of physiological or pathological stimuli. Furthermore, it has been hypothesized that bladder inflammation and neoplastic cell growth, the two most representative pathological conditions of the lower urinary tract, may arise from a primary defective urothelial lining. Transient receptor potential vanilloid channel 1 (TRPV1), a receptor widely distributed in lower urinary tract structures and involved in the physiological micturition reflex, was described to have a pathophysiological role in inflammatory conditions and in the genesis and development of urothelial cancer. In our opinion new compounds, such as curcumin, the major component of turmeric Curcuma longa, reported to potentiate the effects of the chemotherapeutic agents used in the management of recurrent urothelial cancer in vitro and also identified as one of several compounds to own the vanillyl structure required to work like a TRPV1 agonist, could be thought as complementary in the clinical management of both the recurrences and the inflammatory effects caused by the endoscopic resection or intravesical chemotherapy administration or could be combined with adjuvant agents to potentiate their antitumoral effect. |
format | Online Article Text |
id | pubmed-4034493 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-40344932014-06-04 Bladder Cancer and Urothelial Impairment: The Role of TRPV1 as Potential Drug Target Mistretta, Francesco Buffi, Nicolò Maria Lughezzani, Giovanni Lista, Giuliana Larcher, Alessandro Fossati, Nicola Abrate, Alberto Dell'Oglio, Paolo Montorsi, Francesco Guazzoni, Giorgio Lazzeri, Massimo Biomed Res Int Review Article Urothelium, in addition to its primary function of barrier, is now understood to act as a complex system of cell communication that exhibits specialized sensory properties in the regulation of physiological or pathological stimuli. Furthermore, it has been hypothesized that bladder inflammation and neoplastic cell growth, the two most representative pathological conditions of the lower urinary tract, may arise from a primary defective urothelial lining. Transient receptor potential vanilloid channel 1 (TRPV1), a receptor widely distributed in lower urinary tract structures and involved in the physiological micturition reflex, was described to have a pathophysiological role in inflammatory conditions and in the genesis and development of urothelial cancer. In our opinion new compounds, such as curcumin, the major component of turmeric Curcuma longa, reported to potentiate the effects of the chemotherapeutic agents used in the management of recurrent urothelial cancer in vitro and also identified as one of several compounds to own the vanillyl structure required to work like a TRPV1 agonist, could be thought as complementary in the clinical management of both the recurrences and the inflammatory effects caused by the endoscopic resection or intravesical chemotherapy administration or could be combined with adjuvant agents to potentiate their antitumoral effect. Hindawi Publishing Corporation 2014 2014-05-08 /pmc/articles/PMC4034493/ /pubmed/24901005 http://dx.doi.org/10.1155/2014/987149 Text en Copyright © 2014 Francesco Mistretta et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Mistretta, Francesco Buffi, Nicolò Maria Lughezzani, Giovanni Lista, Giuliana Larcher, Alessandro Fossati, Nicola Abrate, Alberto Dell'Oglio, Paolo Montorsi, Francesco Guazzoni, Giorgio Lazzeri, Massimo Bladder Cancer and Urothelial Impairment: The Role of TRPV1 as Potential Drug Target |
title | Bladder Cancer and Urothelial Impairment: The Role of TRPV1 as Potential Drug Target |
title_full | Bladder Cancer and Urothelial Impairment: The Role of TRPV1 as Potential Drug Target |
title_fullStr | Bladder Cancer and Urothelial Impairment: The Role of TRPV1 as Potential Drug Target |
title_full_unstemmed | Bladder Cancer and Urothelial Impairment: The Role of TRPV1 as Potential Drug Target |
title_short | Bladder Cancer and Urothelial Impairment: The Role of TRPV1 as Potential Drug Target |
title_sort | bladder cancer and urothelial impairment: the role of trpv1 as potential drug target |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4034493/ https://www.ncbi.nlm.nih.gov/pubmed/24901005 http://dx.doi.org/10.1155/2014/987149 |
work_keys_str_mv | AT mistrettafrancesco bladdercancerandurothelialimpairmenttheroleoftrpv1aspotentialdrugtarget AT buffinicolomaria bladdercancerandurothelialimpairmenttheroleoftrpv1aspotentialdrugtarget AT lughezzanigiovanni bladdercancerandurothelialimpairmenttheroleoftrpv1aspotentialdrugtarget AT listagiuliana bladdercancerandurothelialimpairmenttheroleoftrpv1aspotentialdrugtarget AT larcheralessandro bladdercancerandurothelialimpairmenttheroleoftrpv1aspotentialdrugtarget AT fossatinicola bladdercancerandurothelialimpairmenttheroleoftrpv1aspotentialdrugtarget AT abratealberto bladdercancerandurothelialimpairmenttheroleoftrpv1aspotentialdrugtarget AT dellogliopaolo bladdercancerandurothelialimpairmenttheroleoftrpv1aspotentialdrugtarget AT montorsifrancesco bladdercancerandurothelialimpairmenttheroleoftrpv1aspotentialdrugtarget AT guazzonigiorgio bladdercancerandurothelialimpairmenttheroleoftrpv1aspotentialdrugtarget AT lazzerimassimo bladdercancerandurothelialimpairmenttheroleoftrpv1aspotentialdrugtarget |